医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

GVK BIO Signs Definitive Agreement to Acquire Vanta Bioscience

2014年11月06日 PM09:00
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

Asia’s leading Discovery Research and Development organization, GVK BIO, announced the signing of a definitive agreement to acquire Vanta Bioscience, a full service preclinical GLP toxicology and safety assessment contract research organization operating out of Chennai, India.

Complying with OECD GLP, ISO, USFDA GLP (21 CFR Part 58 rev. 2009) regulatory guidelines, the company offers toxicology evaluation services for the pharmaceutical, biotech, food supplements and feed additives industries. Vanta Bioscience also offers toxicology services using alternative methods for the Cosmetics industry.

The state-of-the-art facility is GLP and AAALAC accredited, is armed with high-end equipment, and has infrastructure like ‘Individually ventilated Cages’ and ‘Intelligent Building Management’ systems. The facility houses GLP trained scientific personnel with experience and expertise in study design and execution of regulatory directed studies leading to IND filings.

Speaking on the occasion, Manni Kantipudi, CEO, GVK BIO, said: “The acquisition is in line with our business strategy of being an integrated drug discovery services provider for our customers. We are constantly investing in upgrading our capabilities to provide world-class R&D services. Vanta Bioscience further advances our position as we expand our service offering in GLP toxicology.”

Gerard Schwickerath, Vice President and General Manager, Vanta Bioscience, said: “Vanta Bioscience team is pleased that the world-class research GLP and AAALAC accredited organization will continue under the direction of GVK BIO. We are delighted to transition into an organization that can expand our offerings and provide further opportunities to our clients and staff.”

About GVK BIO

GVK Biosciences (GVK BIO) is Asia’s leading Discovery Research and Development organization. GVK BIO provides a broad spectrum of integrated services across the R&D and manufacturing value chain with a focus on speed and quality. GVK BIO capabilities include Discovery Services, Contract Manufacturing, Formulations, Informatics and Clinical Development. www.gvkbio.com

About Vanta Bioscience

Vanta Bioscience offers safety and efficacy assessment services for clients in the pharmaceutical, biotech, medical device, cosmetics, agriculture, food supplements, feed additives and chemical industries, complying with OECD GLP, ISO, USFDA GLP (21 CFR Part 58 rev. 2009) regulatory guidelines. www.vantabio.com

CONTACT

GVK Biosciences
Dorothy Paul
Phone: (91) 40 6692 9904
(D)
dorothy.paul@gvkbio.com
or
Vanta
Bioscience
Gerard Schwickerath
Phone: (1) 515-822-1875
Gerard.Schwickerath@vantabio.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightreeが初のHME向け患者アプリを発表
  • Brightree发布面向居家医疗器械的首个患者App
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表
  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc